Patent and commercial terms in negotiation
Blis Technologies Limited: Ground Floor, 399 Moray Place, Dunedin Central 9016, PO Box 2208, Dunedin 9044, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
14 October 2024
Patent and commercial terms in negotiation
Blis Technologies Limited (BLIS) advised the market on 24 September 2024 that it had become aware
that a key customer, being Bluestone Pharma GmbH (BSP) had filed patents for the BLIS K12™ and
BLIS M18™ fermentation processes, containing BLIS’ confidential information that BLIS had shared
with a manufacturer, being Austrian company Lactosan GmbH & Co. KG (Lactosan) in prior years
under a Non-Disclosure Agreement.
Following the announcement of 24 September 2024, BLIS senior executives have been engaged in
confidential negotiations with BSP and Lactosan to explore possible settlement options in respect of
the alleged contract breaches.
BLIS senior executives travelled to Milan, Italy for the week commencing Monday 7
th
October 2024
to attend the CPHI Milan pharma conference and they also met with BSP and Lactosan
representatives individually to continue negotiations.
These negotiations are ongoing.
No further comment can be made at this stage.
Ends
For further information, please contact:
Scott Johnson
CEO
+64 21 488 831
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS
®
products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.
Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- SML — Synlait Milk Limited: Synlait announces recapitalisation, SSM & FY24 results date2024-08-20
“SYNLAIT 2024 NOTICE OF SPECIAL SHAREHOLDERS’ MEETING 25 As a controlling shareholder, Bright may take Synlait in a different direction For an overview of Bright’s intentions in relation to Synlait’s future, please refer to Bright’s statement in Section 3 (Bright Placement) of…”
- PEB — Pacific Edge Limited: Medicare Coverage Determination Still Under Review2024-07-25
“26 July 2024 MEDICARE COVERAGE DETERMINATION STILL UNDER REVIEW DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) notes that Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab remains in d…”
- SML — Synlait Milk Limited: Synlait Special Shareholders’ Meeting 2024 Presentation2024-09-17
“AN INDEPENDENT ASSESSMENT Overall, Northington Partners concluded that: • on balance and having regard to all relevant factors, the merits of the Bright Dairy placement, The a2 Milk Company placement and The a2 Milk Company settlement outweigh the negative aspects and are i…”